Global Neurology Academy

Updates in Muscular Dystrophy: A Focus on LGMD

Updates in Muscular Dystrophy: A Focus on LGMD

Purpose: To be used in the marketing newsletters as a teaser for the learner and to help with SEO – Search Engine Optimization

In this fast-paced podcast, experts in limb girdle muscular dystrophy discusses the genetic and pathophysiologic underpinnings of LGMD.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Dr. Colin Quinn and Dr. Matthew Wicklund discuss the genetic and pathophysiologic underpinnings of limb girdle muscular dystrophy, as well as the use of appropriate diagnostic tests for accurate identification of LGMD.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures
    The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose. 

    Faculty Disclosures
    The following faculty report that they have relevant financial relationships to disclose: 

    Colin Quinn, MD, has served on the advisory board for Acceleron Pharma, Amicus Therapeutics, and Amylyx Pharmaceuticals. He has also done contract research for Acceleron Pharma, Amicus Therapeutics, Amylyx Pharmaceuticals, Biogen, ImaginAb, Orphazyme, and Sarepta.

    Matthew Wicklund, MD, has served as a consultant for Affinia, Amicus, Edgewise, ML Bio Solutions, Sanofi‐Genzyme, and Sarepta. He has also done contract research for Alexion, ML Bio Solutions, Orphazyme, and Sarepta.

  • Target Audience

    The primary target audience for this activity are neurologists and pediatricians. The secondary target audience are other clinical staff involved in the multidisciplinary management of patients with LGMD

  • Learning Objectives

    Upon completion of this activity, learners should increase their ability to
    • Review the genetic and pathophysiologic underpinnings of LGMD
    • Use appropriate diagnostic tests for accurate identification of LGMD type
  • Accreditation and Credit Designation Statements

    The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an independent educational grant from Sarepta Therapeutics, Inc.

Facebook Comments


We’re glad to see you’re enjoying Global Neurology Academy…
but how about a more personalized experience?

Register for free